[go: up one dir, main page]

JO3271B1 - مشتقات الكوينولين المضادة للجراثيم - Google Patents

مشتقات الكوينولين المضادة للجراثيم

Info

Publication number
JO3271B1
JO3271B1 JOP/2007/0504A JOP20070504A JO3271B1 JO 3271 B1 JO3271 B1 JO 3271B1 JO P20070504 A JOP20070504 A JO P20070504A JO 3271 B1 JO3271 B1 JO 3271B1
Authority
JO
Jordan
Prior art keywords
compounds
quinoline derivatives
pharmaceutically acceptable
treatment
bacterial infection
Prior art date
Application number
JOP/2007/0504A
Other languages
English (en)
Inventor
Koul Anil
Jerome Emile Georges Guillemont
David Francis Alain Lancois
Ismet Dorange
Koenraad Jozef Lodewijk Andries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3271(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3271B1 publication Critical patent/JO3271B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات كوينولين (quinoline derivatives)جديدة مستبدلة طبقا للصيغة العامة (la) او الصيغة (lb): متضمنة اي شكل ايزومري فراغي كيميائيا (stereomically isomeric) منها، بشكل N-اكسيد (N-oxide) من ذلك او بمادة منحلة ( solvate) منها. ان المركبات المحددة تكون مفيدة لمعالجة عدوى بكتيرية (bacterial infection). يتعلق الاختراع بتركيبة تشمل مادة حاملة (carrier) مقبولة دوائياو، كمقوم نشط (active ingredient)، كمية مؤثرة علاجيا من المركبات المحددة، باستخدام المركبات او التركيبات المحددة لتصنيع دواء (medicament) لمعالجة عدوى بكتيرية (bacterial infection) وبعملية لتحضير المركبات المحددة.
JOP/2007/0504A 2006-12-06 2007-11-29 مشتقات الكوينولين المضادة للجراثيم JO3271B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06

Publications (1)

Publication Number Publication Date
JO3271B1 true JO3271B1 (ar) 2018-09-16

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0504A JO3271B1 (ar) 2006-12-06 2007-11-29 مشتقات الكوينولين المضادة للجراثيم

Country Status (32)

Country Link
US (1) US8415475B2 (ar)
EP (1) EP2099758B1 (ar)
JP (1) JP5466011B2 (ar)
KR (1) KR101490222B1 (ar)
CN (2) CN101553470A (ar)
AP (1) AP2479A (ar)
AR (1) AR064151A1 (ar)
AU (1) AU2007328887B2 (ar)
BR (1) BRPI0720220B8 (ar)
CA (1) CA2669819C (ar)
CL (1) CL2007003514A1 (ar)
CY (1) CY1117766T1 (ar)
DK (1) DK2099758T3 (ar)
EA (1) EA016733B1 (ar)
ES (1) ES2573689T3 (ar)
HR (1) HRP20160585T1 (ar)
HU (1) HUE028769T2 (ar)
IL (1) IL199083A (ar)
JO (1) JO3271B1 (ar)
ME (1) ME02498B (ar)
MX (1) MX2009005978A (ar)
MY (1) MY181645A (ar)
NO (1) NO341983B1 (ar)
NZ (1) NZ576823A (ar)
PL (1) PL2099758T3 (ar)
PT (1) PT2099758E (ar)
RS (1) RS54794B1 (ar)
SI (1) SI2099758T1 (ar)
TW (1) TWI406659B (ar)
UA (1) UA100972C2 (ar)
WO (1) WO2008068267A1 (ar)
ZA (1) ZA200903950B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841425B1 (en) 2012-04-27 2016-03-23 Janssen Pharmaceutica, N.V. Antibacterial quinoline derivatives
PT2841426T (pt) 2012-04-27 2016-11-23 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
PT2909192T (pt) 2012-10-16 2017-08-04 Janssen Pharmaceutica Nv Moduladores de ror-gama-t quinolinilo ligados por metileno
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
PH12017501331B1 (en) * 2015-01-27 2024-02-14 Janssen Pharmaceutica Nv Dispersible compositions
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
WO2017155909A1 (en) * 2016-03-07 2017-09-14 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
US20210052597A1 (en) * 2018-01-29 2021-02-25 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
CA3198350A1 (en) * 2020-10-22 2022-04-28 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503411A (ja) * 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
EP1527050B1 (en) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
CA2553266C (en) 2004-01-23 2013-03-12 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
AU2005205935B2 (en) 2004-01-23 2011-06-02 Janssen Pharmaceutica N.V. Quinoline derivatives and use thereof as mycobacterial inhibitors
ATE395336T1 (de) * 2004-01-29 2008-05-15 Janssen Pharmaceutica Nv Chinolinderivate zur verwendung als inhibitoren von mycobakterien
BRPI0510414B1 (pt) * 2004-05-28 2022-04-05 Janssen Pharmaceutica N.V. Combinação e composição farmacêutica
US8088891B2 (en) 2004-09-28 2012-01-03 Janssen Pharmaceutica N.V. Bacterial ATP synthase binding domain
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2952B1 (ar) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2837B1 (ar) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2855B1 (ar) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في مشتقات كوينولين بصفة عوامل مضادة للبكتيريا

Also Published As

Publication number Publication date
CL2007003514A1 (es) 2008-07-11
CY1117766T1 (el) 2017-05-17
CN101553470A (zh) 2009-10-07
JP2010511668A (ja) 2010-04-15
JP5466011B2 (ja) 2014-04-09
KR101490222B1 (ko) 2015-02-05
BRPI0720220B1 (pt) 2020-06-09
AP2009004874A0 (en) 2009-06-30
US20100048566A1 (en) 2010-02-25
EA200970535A1 (ru) 2009-10-30
ME02498B (me) 2017-02-20
NZ576823A (en) 2012-01-12
HK1208437A1 (en) 2016-03-04
MY181645A (en) 2020-12-30
TWI406659B (zh) 2013-09-01
EP2099758B1 (en) 2016-03-09
US8415475B2 (en) 2013-04-09
ES2573689T3 (es) 2016-06-09
EP2099758A1 (en) 2009-09-16
ZA200903950B (en) 2010-08-25
NO20092542L (no) 2009-08-25
HUE028769T2 (en) 2017-01-30
IL199083A (en) 2014-08-31
NO341983B1 (no) 2018-03-05
IL199083A0 (en) 2010-03-28
BRPI0720220A2 (pt) 2013-12-24
WO2008068267A1 (en) 2008-06-12
PL2099758T3 (pl) 2016-08-31
CA2669819A1 (en) 2008-06-12
AR064151A1 (es) 2009-03-18
CN104744361A (zh) 2015-07-01
UA100972C2 (ru) 2013-02-25
DK2099758T3 (en) 2016-06-13
EA016733B1 (ru) 2012-07-30
AU2007328887B2 (en) 2013-01-17
TW200838528A (en) 2008-10-01
PT2099758E (pt) 2016-06-02
KR20090086604A (ko) 2009-08-13
AP2479A (en) 2012-09-27
MX2009005978A (es) 2009-06-16
CN104744361B (zh) 2021-06-08
CA2669819C (en) 2016-08-30
RS54794B1 (sr) 2016-10-31
BRPI0720220B8 (pt) 2021-05-25
AU2007328887A1 (en) 2008-06-12
HRP20160585T1 (hr) 2016-06-17
SI2099758T1 (sl) 2016-07-29

Similar Documents

Publication Publication Date Title
JO3271B1 (ar) مشتقات الكوينولين المضادة للجراثيم
UA101305C2 (ru) Антибактериальные производные хинолина
MX355050B (es) Derivados de quinolina antibacterianos.
JO2725B1 (ar) مشتقات الكوينولين المضادة للجراثيم
JO2685B1 (ar) مشتقات الكوينولين المضادة للجراثيم
JO2970B1 (ar) مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (ar) مشتقات الكوينولين المضادة للجراثيم
MX358506B (es) Derivados de quinolina antibacterianos.
NZ700507A (en) Pyrimidine derivatives for the treatment of bacterial diseases
SG166799A1 (en) Quinoline derivatives as antibacterial agents